Is Novo Nordisk’s Victoza® a New Hope Against Type 2 Diabetes in Adults?
Superior results of HbA1c reduction was shown by Novo Nordisk Victoza® (liraglutide [rDNA origin] injection) in combination with metformin in adults with Type 2 diabetes compared to sitagliptin (100mg ) with metformin in a clinical trial (LIRA-SWITCH).
A 26-week LIRA-SWITCH was a randomized, double-blind, double-dummy, active-controlled trial conducted to check and compare the efficacy of Victoza® over sitagliptin (100 mg) in combination with metformin in a group of 407 adults suffering from Type 2 Diabetes who did not show significant improvement by sitagliptin combined with metformin treatment. Results observed were presented at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016), Boston, Massachusetts.
According to the results Victoza® have been proven to be safe and efficient in reducing HbA1c level among Type 2 diabetic patients. The effectiveness of Victoza® over sitagliptin is as follows:-
- Victoza® administered patients showed substantial body weight reduction compared to those continued with their sitagliptin dose.
- Type 2 diabetes adult patients treated with Victoza® achieved HbA1c targets <7% and ≤6.5% compared to its counterpart sitagliptin.
- Victoza® treated patients showed greater reduction in fasting plasma glucose compared to those treated with sitagliptin.
However some adverse events like gastrointestinal side effects, nausea and diarrhoea were more frequent among Victoza® treated patients over those treated with sitagliptin. No case of hypoglycemia or confirmed nocturnal hypoglycemia were reported in any of the treatments.
Victoza® is an injectable prescription medicine. It is aimed to control blood glucose levels among Type 2 Diabetes patients by stimulating insulin production. Generally, it is prescribed with proper diet and exercise.
“The LIRA-SWITCH trial results provide valuable insight that adults uncontrolled on sitagliptin may achieve a superior reduction with liraglutide 1.8 mg vs continuing on sitagliptin treatment,” said Dr. Maximo Maislos, Atherosclerosis and Metabolism Unit, Soroka UMC, Ben-Gurion University FOHS, Beer Sheva-Israel, and investigator of the LIRA-SWITCH trial. “These findings are valuable as there is limited clinical evidence to guide treatment strategy when people with type 2 diabetes are uncontrolled on second-line therapy.”
Featured image credit: Blood test in medical laboratory, check sugar content diabetes risk © trans961 (Stock Photo ID: 94379192)